What is the best approach to iron replacement in a patient with iron‑deficiency anemia?

Best Approach to Iron Replacement in Anaemic Patients

Start with oral ferrous sulfate 200 mg (≈65 mg elemental iron) once daily plus vitamin C 500 mg for most patients with iron-deficiency anaemia, but switch immediately to intravenous iron if the patient has active inflammatory bowel disease with Hb <10 g/dL, has failed at least two different oral preparations, or requires rapid correction. 1

First-Line Oral Iron Therapy

Ferrous sulfate 200 mg once daily is the gold standard because it provides the most cost-effective treatment with efficacy equal to all other oral formulations. 1, 2

Dosing Strategy

• Take the dose on an empty stomach for maximal absorption; if gastrointestinal side effects occur, taking with food is acceptable. 1
• Once-daily dosing is superior to multiple daily doses because hepcidin remains elevated for approximately 48 hours after each iron dose, blocking subsequent absorption and increasing side effects without improving efficacy. 1, 3
• Add vitamin C 500 mg with each iron dose to markedly enhance absorption, especially critical when transferrin saturation is very low. 1, 2
• Avoid tea and coffee within 1 hour of the iron dose as they strongly inhibit absorption. 1

Alternative Oral Formulations

• If ferrous sulfate is not tolerated, ferrous fumarate (≈106 mg elemental iron) or ferrous gluconate (≈38 mg elemental iron) are equally effective alternatives, though typically more expensive. 1, 2
• No single oral iron formulation has any therapeutic advantage over another—the choice is purely economic. 1

Expected Response and Monitoring

• Hemoglobin should rise by approximately 2 g/dL after 3–4 weeks of adequate oral therapy. 1, 2
• Continue oral iron for 3 months after hemoglobin normalizes to fully replenish iron stores; total treatment duration is typically 6–7 months. 1, 3
• Check hemoglobin at 4 weeks; failure to rise by ≥1 g/dL predicts overall treatment failure and warrants reassessment. 1
• Monitor hemoglobin and red-cell indices every 3 months during the first year, then annually. 1

Absolute Indications for Intravenous Iron (First-Line IV Therapy)

Switch to IV iron immediately—do not persist with ineffective oral therapy beyond 4 weeks. 1

Mandatory IV Iron Scenarios

• Active inflammatory bowel disease with Hb <10 g/dL: Inflammation-driven hepcidin markedly impairs oral absorption and oral iron may worsen inflammation. 1, 4
• Intolerance to at least two different oral iron preparations (e.g., ferrous sulfate and ferrous fumarate). 1, 5
• Post-bariatric surgery patients: Duodenal absorption is anatomically disrupted. 1
• Ferritin fails to improve after 4 weeks of compliant oral therapy. 1
• Chronic heart failure with iron deficiency (ferritin <100 ng/mL or 100–300 ng/mL with transferrin saturation <20%): IV iron improves symptoms and quality of life. 1
• Ongoing gastrointestinal blood loss that exceeds oral replacement capacity. 1, 5

Relative Indications

• Celiac disease with inadequate response to oral iron despite strict gluten-free diet adherence. 1, 4
• Severe symptomatic anaemia requiring rapid correction. 1

Preferred Intravenous Iron Formulations

Choose IV iron products that can replace the entire iron deficit in 1–2 infusions to minimize infusion-related risk and improve convenience. 1, 6

Recommended Formulations

• Ferric carboxymaltose: 750–1000 mg per 15-minute infusion; two doses given ≥7 days apart provide a total of 1500 mg. 1, 6, 2
• Ferric derisomaltose: 1000 mg can be delivered as a single infusion. 1, 2
• Avoid iron dextran as first-line due to higher anaphylaxis risk (≈0.6–0.7%), though true anaphylaxis with any IV iron is rare. 1, 3

Safety Measures

• All IV iron must be administered in a setting equipped with resuscitation facilities. 1, 6, 3
• Most infusion reactions are complement-activation pseudo-allergies that respond to slowing the infusion rate, not true anaphylaxis. 1, 7
• Monitor serum phosphate levels in patients requiring repeat courses, as IV iron (especially ferric carboxymaltose) can cause hypophosphatemia. 6, 2

Special Population Considerations

Inflammatory Bowel Disease

• IV iron is mandatory first-line when Hb <10 g/dL with active inflammation; oral iron is poorly absorbed and may exacerbate disease. 1, 4
• For mild anaemia (Hb >10 g/dL) with quiescent disease, oral iron may be used if absorption is adequate. 1
• Treat active inflammation first to enhance iron absorption. 1

Pregnancy

• Start oral low-dose iron 30 mg/day at first prenatal visit for prevention. 1
• Treat anaemia with 60–120 mg/day elemental iron. 1
• IV iron is safe and effective during second and third trimesters when oral iron fails. 1

Chronic Kidney Disease

• IV iron is preferred for dialysis patients. 1
• Either IV or oral iron for non-dialysis CKD stages 3–5. 1

Critical Pitfalls to Avoid

• Do not prescribe multiple daily oral doses—this increases side effects without improving efficacy due to hepcidin-mediated absorption blockade. 1, 3
• Do not stop iron therapy when hemoglobin normalizes—continue for an additional 3 months to replenish stores. 1, 2
• Do not persist with oral iron beyond 4 weeks without a hemoglobin rise—reassess for malabsorption, ongoing loss, or need for IV iron. 1, 5
• Do not use oral iron in active IBD patients with Hb <10 g/dL—IV iron is the appropriate first-line option. 1, 4
• Do not overlook vitamin C supplementation when oral iron response is suboptimal. 1, 2
• Do not fail to identify and treat the underlying cause of iron deficiency while providing supplementation. 1, 5

Algorithm for Non-Response to Oral Iron

If hemoglobin fails to rise adequately after 4 weeks:

1. Verify adherence to oral therapy. 1
2. Evaluate for ongoing blood loss (occult GI bleeding, menorrhagia). 1, 8
3. Consider malabsorption syndromes (celiac disease, IBD, post-bariatric surgery). 1, 4
4. Check for concurrent vitamin B12 or folate deficiency. 1
5. Assess for systemic disease or bone-marrow pathology. 1
6. Switch to intravenous iron if oral therapy failure is confirmed. 1, 5